ASTRAZENECA SP ADR (ZEGA MU) stock market data APIs
€72.3641
0(0%)
as of October 17, 2025
Try our APIs with
free plan!
ASTRAZENECA SP ADR Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ZEGA.MU.
Prev. Close
72.3641
Open
72.3641
High
72.3641
Low
72.3641
52 wk Range
58.5906-73.5
Market Cap
148 612 M
Dividends (Yield)
0.0227
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ASTRAZENECA SP ADR data using free add-ons & libraries
Get ASTRAZENECA SP ADR Fundamental Data
ASTRAZENECA SP ADR Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ASTRAZENECA SP ADR News
New
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
More than 92% of patients treated with AstraZeneca and Daiichi Sankyo’s ENHERTU were free of invasive disease at three years DESTINY-Breast05 presented in ESMO Presidential Symposium alongside DEST...
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO. Continue Reading View Comments
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
Highest reported pathologic complete response rate seen in a Phase III registrational trial for HER2-positive early breast cancer with favorable safety profile vs. standard treatment DESTINY-Breast11...
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
Astrazeneca (AZN) closed at $84.69 in the latest trading session, marking a +1.03% move from the prior day. This change outpaced the S&P 500's 0.53% gain on the day. Elsewhere, the Dow gained 0.52%, w...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
